drugset / Trial / NCT00399971
Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia
Phase 1/2
Unknown
100 enrolled
Shenzhen Zhongxing Yangfan Biotech Co. Ltd.
Liu Hua Qiao Hospital · collabThe 12th Guangzhou Municipal Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Our hypothesis is that ex vivo activated immune cells would produce multiple known and unknown potent hematopoietic cytokines, working in concert, these cytokines help stem cell growth and differentiation. Additionally, these cells travel and home to bone marrow as well as spleen and liver involved in hematopoietic activities, where direct cell-cell contact may be beneficial.
Timeline
- Start
- 2002-11
- Primary completion
- 2009-06
- Completion
- 2009-12
Publications
- Background Chen J, Liu W, Wang X, Chen H, Wu J, Yang Y, Wu L, Yang D. Ex vivo immunotherapy for patients with benzene-induced aplastic anemia. J Hematother Stem Cell Res. 2003 Oct;12(5):505-14. doi: 10.1089/152581603322448213.
- Background Li G, Wang X, Wu L, Zhang W, Chen H, Xie Y, Yang D. Ex vivo activated immune cells promote survival and stimulate multilineage hematopoietic recovery in myelosuppressed mice. J Immunother. 2005 Jul-Aug;28(4):420-5. doi: 10.1097/01.cji.0000170360.99714.3f.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ex vivo immunotherapy | Cell therapy | — | Intravenous |